We are ready for #SGOmtg on March 14-17, 2025, in Seattle, Washington! US HCPs: We are excited to have both an oral and a poster presentation at this year’s SGO Annual Meeting! We will also host an industry-supported symposium on March 17 from 12:00-1:30 pm on the evolving #EndometrialCancer landscape. Hope to see you there! Please stop by our medical exhibit booth (#624) to learn more! #EndometrialCancer #BelieversinScience??
Karyopharm Medical Affairs
制药业
Karyopharm Medical Affairs delivers timely communications of medical scientific information intended for US HCPs.
关于我们
The goal of the Karyopharm Medical Affairs LinkedIn page is to deliver timely communication of medical and scientific information regarding Karyopharm Therapeutics, Inc. products and the relevant diseases with US healthcare professionals (HCPs). We will share information about scientific data presented at medical congresses, published in peer-reviewed journals, clinical studies that are newly posted on clinicaltrials.gov, clinical studies that are recruiting, and relevant disease-related information. Extraordinary persistence, grit and unwavering passion drive our commitment to the delivery of scientific innovation. It’s the extraordinary strength and courage of patients who fuel our continued pursuit. By engaging with the Karyopharm Medical Affairs LinkedIn page, you confirm that you are a US HCP, and agree to receive information from Karyopharm Medical Affairs LinkedIn page according to the Terms & Conditions provided by LinkedIn (www.dhirubhai.net/legal/user-agreement). Content posted on this account should not be shared outside the US and contents not posted by Karyopharm Therapeutics do not reflect our views or opinions and we do not guarantee their accuracy or reliability. Our posts are intended to share scientific information and should not be viewed as medical advice and may include content about uses of Karyopharm products that may not be approved by the FDA. Karyopharm cannot make any clinical recommendations or provide medical treatment advice. Any information provided on this site should not take the place of your own independent medical judgment. If you have any questions about a specific Karyopharm Therapeutics product, please contact Karyopharm Therapeutics Medical Information at [email protected]. Please report any side effects from any of our products or product quality complaints by calling 1-888-209-9326. Channel run by https://karyopharm.com/
- 网站
-
https://www.karyopharmmedicalaffairs.com/
Karyopharm Medical Affairs的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Newton
- 类型
- 上市公司
- 创立
- 2008
- 领域
- oncology、pharmaceutical、biotech、multiple myeloma、lymphoma、solid tumors、endometrial cancer、clinical research、research、clinical trials、drug discovery、medical和healthcare
地点
-
主要
获取路线
85 Wells Avenue
US，Newton，MA 02459
Karyopharm Medical Affairs员工
动态
-
US HCPs: We have published a retrospective #RealWorldData Exploratory analysis in patients with relapsed/refractory #MultipleMyeloma???? https://lnkd.in/gKDNzrQb
-
Thanks to the #ESGO2025 organizers for a fantastic congress in Rome, Italy!?We found it incredibly rewarding to connect with so many passionate physicians and experts in the field.? ? For US HCPs who couldn’t join us, be sure to check out the Congresses & Publications section on the Karyopharm Medical Affairs website for more information. https://lnkd.in/e_wBcybv #BelieversinScience?
-
US HCPs: We are excited to kick off 2025 with an oral presentation reporting long term analyses from the Phase 3 SIENDO trial evaluating an XPO1 inhibitor as a maintenance therapy in patients with TP53 wild type advanced/recurrent #EndometrialCancer?at the #ESGO2025 26th?European Gynaecological Oncology Congress from February 20-23, 2025, in Rome, Italy!??
-
US HCPs: We have published the Phase 3 SENTRY study design in Future Oncology. SENTRY is evaluating the efficacy and safety of a XPO1 inhibitor + ruxolitinib for patients with JAKi-na?ve #Myelofibrosis. This trial is currently recruiting patients!? https://lnkd.in/ggVgGjHv
-
Attention US HCPs! The rapid expansion of available T-cell redirecting therapies (TCRT) for Multiple Myeloma has brought to the fore a need for evidence-based recommendations on sequencing immunotherapies. #MultipleMyeloma Read more about XPO1 inhibition and recommendations from the International Myeloma Working Group: https://lnkd.in/gA2HStKj
-
-
ATTENTION US HCPs! Phase 3 SENTRY is evaluating the efficacy and safety of selinexor + ruxolitinib for patients with JAKi-na?ve #Myelofibrosis. This study is actively enrolling participants!?https://lnkd.in/gGnG4f85?
-
ATTENTION US HCPs! Phase 3 SENTRY is evaluating the efficacy and safety of selinexor + ruxolitinib for patients with JAKi-na?ve #Myelofibrosis. This study is actively enrolling participants!?https://lnkd.in/gGnG4f85?
-
?? US HCPs can now easily find their local Karyopharm Medical Science Liaison by using the MSL locator on our GMSA website.? ? https://lnkd.in/dT7_4SuP? #BelieversinScience?
-
#US HCPs, we have a new addition to our GMSA website! Visit https://lnkd.in/gbwFRcs4 for more information. #BelieversinScience
-